V09 DIAGNOSTIC RADIOPHARMACEUTICALS
An expert group consisting of Dik Blok (the Netherlands), Per Oscar Bremer (Norway) and Trygve Bringhammar (Sweden) is responsible for the ATC classification of radiopharmaceuticals in V09 and V10. The group has also prepared the guidelines for classification of these products.
Radiopharmaceuticals for diagnostic use are classified in this group, while radiopharmaceuticals for therapeutic use are classified in V10. In general, the 3rd level are subdivided according to site of action or organ system, the 4th level according to radionuclide and the 5th level specifies the chemical substance. The ATC 5th level defines the actual form essential in nuclear medicine procedures, which includes radionuclide and carrier molecule. Therefore, products on the market, that can often be regarded as intermediate products rather than ready-to-use radiopharmaceuticals, can be given more than one (5th level) ATC code, e.g. Technetium (99mTc) exametazime (V09AA01) and technetium (99mTc) exametazime labelled cells (V09HA02).
ATC codes are not assigned for radionuclide precursors which are used only in the radiolabelling of another substance prior to administration.
V09H INFLAMMATION AND INFECTION DETECTION
This group comprises agents for the detection of inflammation and infection. Labelled blood cells are classified in this group. Agents that are used for the labelling of these cells can also be classified elsewhere, e.g. technetium-exametazime is classified in V09A -Central Nervous System. No subdivision is made for the type of labelled cells (erythrocytes, granulocytes or autologous etc.).
V09HA Technetium (99mTc) compounds
|V09HA02||technetium (99mTc) exametazime labelled cells|
Last updated: 2013-12-19